Safety and efficacy of fixed-dose combination calcipotriol (50 μg/g) and betamethasone dipropionate (0.5 mg/g) cutaneous foam in adolescent patients (aged 12 to <17 years) with plaque psoriasis: results of a phase II, open-label trial.
Marieke Martha Benedicta SeygerW AbramovitsM LiljedahlM N HoejenJ TengPublished in: Journal of the European Academy of Dermatology and Venereology : JEADV (2020)
Cal/BD foam was well tolerated in adolescent patients with body/scalp psoriasis. There was no evidence for dysregulation of the HPA-axis nor calcium homoeostasis in patients with more severe disease. Exploratory efficacy data in the overall population were encouraging.
Keyphrases
- phase ii
- open label
- clinical trial
- phase iii
- end stage renal disease
- young adults
- mental health
- newly diagnosed
- study protocol
- chronic kidney disease
- peritoneal dialysis
- placebo controlled
- coronary artery disease
- double blind
- electronic health record
- early onset
- patient reported outcomes
- machine learning
- big data
- drug induced
- data analysis